Loading...
Loading...
A validation-forward, end-to-end journey for a generalized chimpanzee/simian adenovirus (ChAd-class) vaccine, from vector rescue and HEK293 perfusion upstream through downstream control strategy, risk-based validation, PPQ, and continued process verification.
Track vector rescue → USP → DSP → FMEA → CQV/PPQ artifacts on a 30-month program timeline mapped to the FDA Stage 1–3 validation lifecycle.
Bringing a chimpanzee/simian adenovirus vaccine from vector rescue to a validated commercial process is a coupled upstream, downstream, and regulatory challenge. This playbook walks the full lifecycle and links the relevant platform suite at every stage, with validation woven throughout.
Tools marked Public Preview open immediately. Items marked Access Required link to the tool but redirect to sign-in or an invite unless you have platform access.
Work top to bottom — each stage links the platform tools for that phase of validation.
Adenoviral process design starts with the vector and the cell substrate. Recover infectious virus from the genome plasmid, bank a qualified working virus stock and HEK293 cell bank, and define the Critical Quality Attributes (identity, infectious titer, VP:IVP ratio, residual host-cell DNA, adventitious agents). Per the FDA 2011 Process Validation guidance, this is Stage 1, and a qualified small-scale model is the foundation that makes later process characterization and PPQ defensible (ICH Q8/Q11).
Key Questions at This Stage
Upstream sets the yield ceiling. The three canonical adenovirus CPPs (cell density at infection, MOI, and production pH) interact non-linearly, and the cell-density effect can collapse per-cell productivity unless perfusion/cell-retention is used. Characterizing the intensified perfusion process (the public-domain route to >4x volumetric productivity) and defining proven acceptable ranges is the heart of Stage 1 process characterization (ICH Q8 design space; ICH Q11 control strategy).
Key Questions at This Stage
The clarified harvest flows into capture and polishing: anion-exchange chromatography for the highly negatively charged adenovirus capsid, followed by TFF/UF-DF for concentration and buffer exchange. Map CPPs to CQAs across the train and define the control strategy: impurity clearance (host-cell protein, DNA, empty capsids), the VP:IVP ratio, and final formulation. The USP Control Room hands the clarified bulk titer and volume straight into the DSP Control Room (ICH Q8–Q11).
Key Questions at This Stage
A risk-based validation program (ICH Q9) prioritizes where to spend validation effort. For a replication-deficient adenoviral vector, viral safety is paramount: adventitious agent control, replication-competent adenovirus (RCA) testing, and viral clearance rationale. Build the FMEA, risk register, and CPP/CQA criticality assessment that justify PPQ parameter ranges and sampling, exactly the package an inspector expects against 21 CFR 210/211, 600–610 and EU Annex 1.
Key Questions at This Stage
Process Performance Qualification (Stage 2) demonstrates the commercial process reproducibly delivers quality product. Author the Validation Master Plan and PPQ protocols: batch-selection rationale, acceptance criteria, sampling plans, and the statistical approach for demonstrating consistency. For programs run at a CDMO, this stage is equally about external-partner oversight: tech-transfer package, facility/equipment qualification (Stage 2A), and Quality Agreement alignment.
Key Questions at This Stage
Platform Tools
CDMO Dashboard
Checking access…External-partner batch tracking and program KPIs
PM & Scope Control Suite
Checking access…Scope cascade, change impact, and program control
Tech Transfer Package
Checking access…CPP/CQA, equipment fit, analytical transfer, documentation index
Commissioning & CQV Suite
Checking access…Facility/equipment qualification (Stage 2A) and PPQ readiness
Process Validation & Qualification Suite
Checking access…PPQ batch analysis, sampling plans (ISO 2859-1), statistical acceptance criteria
Generate PPQ Protocol (ChAd)
Checking access…VMP / PPQ Protocol document draft with ChAd-specific CPPs and CQAs
CAPEX / OPEX Calculator
Checking access…Equipment and operational cost modeling
Execute the PPQ conformance lots, then transition to Stage 3, Continued Process Verification. Ongoing monitoring with control charts (Cpk/Ppk), trend analysis, and a robust deviation/CAPA system demonstrates the process stays in a state of control across its commercial life. This is where MSAT, supply, and CDMO oversight converge on a single source of truth for inspection-ready records.
Key Questions at This Stage
Platform Tools
SPC & PPQ Dashboard
Checking access…Shewhart charts, Nelson rules 1–8, Cp/Cpk/Pp/Ppk, batch overlay ANOVA for CPV
CPV Monitoring (Stage 3)
Checking access…CPV monitoring schedule, OOT/OOS tracker, APR framework — ICH Q10 §3.2
Workspace Dashboard
Checking access…ChAd program overview and cross-tool KPIs
CDMO Dashboard
Checking access…Vendor batch and capacity oversight
Supply Forecasting
Checking access…Monte Carlo demand and inventory modeling
Optional — process train shortcuts
Skip ahead on the USP → clarification → DSP → formulation train without scrolling the full stage list.
Start in the USP Control Room, send the clarified harvest to the DSP Control Room, then save snapshots to the ChAd program dashboard to see the artifacts populate the lifecycle.
Public-domain demonstration. This case study is an independent engineering portfolio piece built entirely from publicly available literature on adenoviral-vector manufacturing and the FDA/ICH process-validation framework. It does not represent, and is not affiliated with, any specific organization's proprietary process, product, or data.